15
Participants
Start Date
October 31, 2016
Primary Completion Date
December 31, 2018
Study Completion Date
December 31, 2018
Secukinumab
Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.
UCSF Psoriasis and Skin Treatment Center, San Francisco
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
University of California, San Francisco
OTHER